Market Access News | pharmaphorum

News

CDER head Tidmarsh 'on leave' and is sued by drugmaker

George Tidmarsh is no longer at the helm of CDER and is facing a lawsuit claiming he abused his position there to harm a former business associate.

News

"Significant shift" as NICE widens prostate cancer drug use

NICE has changed unpopular guidance on abiraterone for hormone-sensitive prostate cancer after the entry of generics into the UK market.

News

FDA plan will cut testing requirements for biosimilars

The FDA has proposed a radical change to the regulatory requirements for bringing biosimilar medicines to market as a way to cut US drug prices.

News

Chugai buys 'Asia lag' firm Renalys for $98m upfront

Chugai Pharma has reached a deal to buy Renalys Pharma, a company set up to bring therapies developed elsewhere to markets in Asia.

News

A male HCP discusses treatment with an older male patient

Bayer's prostate cancer drug Nubeqa cleared for NHS use

Thousands of men living with incurable prostate cancer will be able to access an easier-to-tolerate treatment from Bayer, thanks to new NICE guidance.

News

ICER says US new drug launch prices have risen sharply

ICER says the prices of new drug launches in the US rose 51% in three years, adding up to $1.5bn in first-year costs to US health systems.

CDER head Tidmarsh 'on leave' and is sued by drugmaker

"Significant shift" as NICE widens prostate cancer drug use

FDA plan will cut testing requirements for biosimilars

Chugai buys 'Asia lag' firm Renalys for $98m upfront

Bayer's prostate cancer drug Nubeqa cleared for NHS use

ICER says US new drug launch prices have risen sharply

NICE backs stomach cancer, PAH drugs for NHS use

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks